MBX Biosciences, Inc.
MBXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How MBX's past catalysts played out
MBX 2109
Hypoparathyroidism
400 µg of MBX 2109 once-weekly by subcutaneous injection
Hypoparathyroidism
MBX 1416 (INN imapextide)
Postbariatric Hypoglycemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MBX 2109 | Phase 2 | Hypoparathyroidism | - | - |
400 µg of MBX 2109 once-weekly by subcutaneous injection | Phase 2 | Hypoparathyroidism | - | - |
MBX 1416 (INN imapextide) | Phase 2 | Postbariatric Hypoglycemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MBX Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in MBX Biosciences, Inc.'s (MBX) pipeline across Phase 2. Its lead program is MBX 2109 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MBX Biosciences, Inc.'s next FDA catalyst?→
MBX Biosciences, Inc.'s (MBX) next tracked catalyst is a Phase 2 expected May 27, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MBX biotech catalysts?→
Add MBX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MBX Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.